-
Je něco špatně v tomto záznamu ?
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
S. Goldman-Mazur, A. Jurczyszyn, JJ. Castillo, A. Waszczuk-Gajda, N. Grząśko, J. Radocha, M. Bittrich, KM. Kortüm, A. Gozzetti, L. Usnarska-Zubkiewicz, J. Davila Valls, DS. Jayabalan, R. Niesvizky, J. Kelman, D. Coriu, L. Rosiñol, Ł. Szukalski,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
NLK
Free Medical Journals
od 1998 do Před 1 rokem
Wiley Free Content
od 1996 do Před 1 rokem
PubMed
32072687
DOI
10.1002/ajh.25758
Knihovny.cz E-zdroje
- MeSH
- doba přežití bez progrese choroby MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom genetika mortalita MeSH
- retrospektivní studie MeSH
- translokace genetická MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
The t(14;16) translocation, found in 3%-5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real-world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7-18.7), the median progression-free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5-2.4) and 4.1 years (95% CI 3.3-5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05-2.58]), as well as revised International Scoring System (R-ISS) 3 (vs R-ISS 2; HR = 2.59, 95% CI [1.59-4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R-ISS 3 predict poor survival.
Complejo Asistencial de Avila Avila Spain
Department of Cancer Prevention Medical University of Silesia Katowice Poland
Department of Clinical Oncology Maria Sklodowska Curie National Institute of Oncology Cracow Poland
Department of Hematology Jagiellonian University Medical College Cracow Poland
Department of Hematology Oncology and Internal Diseases Warsaw Medical University Warsaw Poland
Department of Hematology Oncology Medstar Georgetown University Hospital Washington DC
Department of Hematology SPZOZ ZSM in Chorzów Chorzów Poland
Department of Hematology UZ Leuven Leuven Belgium
Department of Infectious and Tropical Diseases Jagiellonian University Medical College Cracow Poland
Department of Internal Medicine 2 University Hospital Würzburg Würzburg Germany
Department of Medicine Queen Mary Hospital University of Hong Kong Pokfulam Hong Kong
Department of Medicine Warren Alpert Medical School Brown University Providence Rhode Island
Hematology Department of Medical Science Surgery and Neuroscience University of Siena Siena Italy
Hematology Unit AO Cosenza Cosenza Italy
Hospital Universitario de Salamanca Instituto Biosanitario de Salamanca Salamanca Spain
Institute of Hematology and Transfusion Medicine Warsaw Poland
John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey
Medical University of Lódź Lódź Poland
Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023045
- 003
- CZ-PrNML
- 005
- 20201214125203.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.25758 $2 doi
- 035 __
- $a (PubMed)32072687
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Goldman-Mazur, Sarah $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland.
- 245 12
- $a A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma / $c S. Goldman-Mazur, A. Jurczyszyn, JJ. Castillo, A. Waszczuk-Gajda, N. Grząśko, J. Radocha, M. Bittrich, KM. Kortüm, A. Gozzetti, L. Usnarska-Zubkiewicz, J. Davila Valls, DS. Jayabalan, R. Niesvizky, J. Kelman, D. Coriu, L. Rosiñol, Ł. Szukalski, V. González-Calle, MV. Mateos, K. Jamroziak, I. Hus, I. Avivi, Y. Cohen, A. Suska, A. Chappell, D. Madduri, S. Chhabra, A. Kleman, P. Hari, M. Delforge, P. Robak, M. Gentile, I. Kozłowska, SL. Goldberg, J. Czepiel, R. Silbermann, AJ. Olszewski, P. Barth, G. Mikala, CS. Chim, M. Długosz-Danecka, S. Grosicki, DH. Vesole,
- 520 9_
- $a The t(14;16) translocation, found in 3%-5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real-world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7-18.7), the median progression-free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5-2.4) and 4.1 years (95% CI 3.3-5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05-2.58]), as well as revised International Scoring System (R-ISS) 3 (vs R-ISS 2; HR = 2.59, 95% CI [1.59-4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R-ISS 3 predict poor survival.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x genetika $x mortalita $7 D009101
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a translokace genetická $7 D014178
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Jurczyszyn, Artur $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland.
- 700 1_
- $a Castillo, Jorge J $u Division of Hematological Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- 700 1_
- $a Waszczuk-Gajda, Anna $u Department of Hematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland.
- 700 1_
- $a Grząśko, Norbert $u Department of Experimental Hematology, Medical University of Lublin, Lublin, Poland. Department of Hematology, St. John's Cancer Center, Lublin, Poland.
- 700 1_
- $a Radocha, Jakub $u 4th Department of Internal Medicine- Hematology, University Hospital and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Bittrich, Max $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
- 700 1_
- $a Kortüm, K Martin $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
- 700 1_
- $a Gozzetti, Alessandro $u Hematology, Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy.
- 700 1_
- $a Usnarska-Zubkiewicz, Lidia $u Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
- 700 1_
- $a Davila Valls, Julio $u Complejo Asistencial de Avila, Avila, Spain.
- 700 1_
- $a Jayabalan, David S $u Weill Cornell Medical College, New York, New York.
- 700 1_
- $a Niesvizky, Ruben $u Weill Cornell Medical College, New York, New York.
- 700 1_
- $a Kelman, Julia $u Weill Cornell Medical College, New York, New York.
- 700 1_
- $a Coriu, Daniel $u Department of Hematology, Fundeni Clinical Institute, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
- 700 1_
- $a Rosiñol, Laura $u Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
- 700 1_
- $a Szukalski, Łukasz $u Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.
- 700 1_
- $a González-Calle, Veronica $u Hospital Universitario de Salamanca/ Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.
- 700 1_
- $a Mateos, Maria V $u Hospital Universitario de Salamanca/ Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.
- 700 1_
- $a Jamroziak, Krzysztof $u Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
- 700 1_
- $a Hus, Iwona $u Department of Experimental Hematology, Medical University of Lublin, Lublin, Poland. Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
- 700 1_
- $a Avivi, Irit $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Cohen, Yael $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Suska, Anna $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland.
- 700 1_
- $a Chappell, Aimee $u Department of Hematology/Oncology, Medstar Georgetown University Hospital, Washington DC.
- 700 1_
- $a Madduri, Deepu $u Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- 700 1_
- $a Chhabra, Saurabh $u Division of Hematology/Oncology Department of Medicine Medical College of Wisconsin, Milwaukee, Wisconsin.
- 700 1_
- $a Kleman, Ariel $u Division of Hematology/Oncology Department of Medicine Medical College of Wisconsin, Milwaukee, Wisconsin.
- 700 1_
- $a Hari, Parameswaran $u Division of Hematology/Oncology Department of Medicine Medical College of Wisconsin, Milwaukee, Wisconsin.
- 700 1_
- $a Delforge, Michel $u Department of Hematology, UZ Leuven, Leuven, Belgium.
- 700 1_
- $a Robak, Paweł $u Medical University of Lódź, Lódź, Poland.
- 700 1_
- $a Gentile, Massimo $u Hematology Unit, AO Cosenza, Cosenza, Italy.
- 700 1_
- $a Kozłowska, Izabela $u Department of Hematology, SPZOZ ZSM in Chorzów, Chorzów, Poland.
- 700 1_
- $a Goldberg, Stuart L $u John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. Cota Inc., New York, New York.
- 700 1_
- $a Czepiel, Jacek $u Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, Cracow, Poland.
- 700 1_
- $a Silbermann, Rebecca $u Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
- 700 1_
- $a Olszewski, Adam J $u Department of Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island.
- 700 1_
- $a Barth, Peter $u Department of Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island.
- 700 1_
- $a Mikala, Gabor $u Department of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute of Hematology and Infectology, Budapest, Hungary.
- 700 1_
- $a Chim, Chor S $u Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong.
- 700 1_
- $a Długosz-Danecka, Monika $u Department of Clinical Oncology, Maria Sklodowska-Curie National Institute of Oncology, Cracow, Poland.
- 700 1_
- $a Grosicki, Sebastian $u Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland.
- 700 1_
- $a Vesole, David H $u John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 95, č. 5 (2020), s. 503-509
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32072687 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125203 $b ABA008
- 999 __
- $a ok $b bmc $g 1595364 $s 1113721
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 95 $c 5 $d 503-509 $e 20200229 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- LZP __
- $a Pubmed-20201125
